Emyria and PAX Centre have announced a collaboration to develop a care model for psilocybin-assisted therapy in addition to their existing MDMA-assisted therapy care model.
The collaboration aims to address substantial overlap between symptoms of depression and PTSD – conditions with growing prevalence – by expanding treatment offerings available for patients with either or both conditions.
Dr. Ben Sessa, internationally renowned psychiatrist, MDMA researcher and recently appointed teaching faculty at Mind Medicine Australia, has been engaged to provide therapist training across MDMA and psilocybin.
Emyria aims to establish a network of trained therapists and psychiatrists to provide MDMA-assisted therapy to appropriately diagnosed patients from July 1st, 2023, through ethics-approved clinical trials and the Authorised Prescriber pathway.
Read more at our investor hub: ASX Announcements | Emyria Investor Hub